Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate


Departments of Medicine, 1Surgery and 2Histopathology, Bristol Royal Infirmary, Bristol BS2 8HW, UK

Summary: Parathyroid carcinoma is rare and the associated hypercalcaemia is often resistant to all treatment. A case is described in which prolonged control of hypercalcaemia has been achieved by infrequent infusions of pamidronate despite continuing hypersecretion of parathyroid hormone.

Introduction

Carcinoma of the parathyroid glands is a rare tumour accounting for approximately 1% of all causes of primary hyperparathyroidism.1 Most tumours are functional, causing severe hypercalcaemia which is often resistant to all modes of treatment. We report a case which has shown prolonged remissions of hypercalcaemia following single infusions of 15 mg of intravenous pamidronate (aminohydroxypropylidine diphosphonate, APD) despite evidence of continuing hypersecretion of parathyroid hormone from residual tumour.

Case report

A 47 year old white female developed recurrent nephrolithiasis in 1977 and was found to have nephrocalcinosis and a serum calcium of 3.0 mmol/l (NR 2.25–2.7). She underwent right lower neckectomy in 1980. In 1981 serum calcium remained elevated at 3.12 mmol/l and serum parathyroid hormone (PTH) was 156 pmol/l (NR <60), suggesting primary hyperparathyroidism. At another hospital a right lower parathyroid tumour measuring 1 × 1.5 cm was removed and reported as an adenoma. From 1981 to 1984 she remained normocalcaemic. She presented again in January 1988 with symptomatic hypercalcaemia. Serum calcium was 3.5 mmol/l with PTH elevated at 302 pmol/l.

Re-explorations of neck and mediastinum in May and December 1988 failed to identify parathyroid tissue. During a fourth surgical exploration in May 1989, aided by results of selective angiography and venous sampling for PTH, a nodule was excised along with the right thyroid lobe. Histology of the nodule was reported as parathyroid carcinoma with evidence of fibrous septae, invasion of contiguous structures, abnormal mitoses and parastracheal lymph node involvement. Review of the 1981 histology indicated that the original parathyroid tumour was in fact a carcinoma.

Following a brief postoperative period of hypercalcaemia she became hypercalcaemic within 3 months. In February 1990, in view of symptoms (serum calcium 2.86 mmol/l), she was admitted for a trial of intravenous pamidronate infusion receiving 15 mg. Withing 5 days she became normocalcaemic and remained so for 22 months, although serum PTH levels remained persistently elevated (1.4–7.8 × upper limit of normal). When hypercalcaemia (2.9 mmol/l) recurred after 22 months she was treated with a second infusion of 15 mg of pamidronate, and normocalcaemia was restored within 3 days and maintained for 9 months. A third recurrence was controlled for 6 months and a fourth infusion for further hypercalcaemia has, to date, controlled the situation for one month. No features to suggest MEN Type I have appeared and throughout she has not been exposed to drugs affecting calcium metabolism. The patient's biochemical course is displayed in Figure 1.

Discussion

Parathyroid carcinoma is a rare tumour with approximately 100 reported cases.1 Multifocal parathyroid malignancy is unusual and accidental parathyroid autotransplantation occurring during neck surgery can result in quasi-malignant histological appearances. Despite this and the notorious difficulties of endocrine histological diagnosis, repeated reviews, and the presence of lymph node involvement, indicate that the diagnosis of parathyroid malignancy is correct.

Correspondence: Paul Newrick, M.D., M.R.C.P., Diabetes & Endocrine Unit, Bristol Royal Infirmary, Bristol BS2 8HW, UK.
Accepted: 10 August 1993
Bisphosphonates are an established treatment for malignant hypercalcaemia, although early recurrence of hypercalcaemia within weeks is common. The mechanism of their action is via a decrease in bone resorption. Short-term studies with clodronate\(^2\) and pamidronate\(^3\) have shown reductions of serum calcium in primary hyperparathyroidism. The results of previous reports of medical treatment for recurrent hyperparathyroidism of parathyroid carcinoma, however, are disappointing.

Oestrogens, calcitonin and mithramycin offer only short-term benefit. Intravenous clodronate, 500 mg three times weekly, has been reported as useful in this situation, also with no change in elevated PTH levels.\(^4\) In one case\(^5\) serum calcium was lowered but not normalized by oral pamidronate given for 3 months with a suggestion of lowered PTH levels.

The present case is highly unusual in that a single dose of intravenous pamidronate produced 22 months of normocalcaemia. Second and third doses subsequently achieved control for 9 and 6 months, respectively. The duration of the response is surprising. Parathyroid infarction is a possibility but the evidence of continued tumour activity as judged by elevated PTH levels suggests prolonged uncoupling of the bone resorption—formation cycle following pamidronate. Unfortunately we do not have urinary calcium studies to demonstrate whether the normocalcaemic state is truly consecutive to inhibition of bone resorption rather than renal tubular calcium leak, although this latter seems very unlikely given the recurrent nature of the hypercalcaemia in the face of relatively stable renal function.

Such control of hypercalcaemia in parathyroid carcinoma with a bisphosphonate may be very rare but is worthy of consideration in all such patients and might even prolong survival.

References

Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.


doi: 10.1136/pgmj.70.821.231

Updated information and services can be found at:
http://pmj.bmj.com/content/70/821/231

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/